New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
11:23 EDTBIIBRoyalty Pharma acquires additional interest in TECFIDERA for $510M
Royalty Pharma announced earlier that it has acquired an additional interest in the earn-out payable to the former shareholders of Fumapharm AG for $510M in cash. The Fumapharm earn-out primarily represents an indirect interest in sales of Biogen Idec's TECFIDERA, an oral therapeutic for the treatment of relapsing-forms of multiple sclerosis. The earn-out also includes an indirect interest in sales of FUMADERM, a therapeutic approved in Germany for the treatment of moderate to severe plaque psoriasis.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
January 14, 2015
07:05 EDTBIIBIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 13, 2015
13:09 EDTBIIBBiogen CEO says company has strengthened R&D, to stay active in M&A
Subscribe for More Information
January 11, 2015
20:06 EDTBIIBBiogen acquires U.K.-based Convergence for up to $675M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use